Unternehmen wird geladen
Moderna, Inc.
MRNA · Nasdaq · ·
223,22 $-3,5 %Schluss 13. Nov.
Zahlen bis 30. September 2026, aus dem 10-Q vom 6. November 2026
Wertentwicklung in der Vergangenheit
- 1W
- -12,2 %
- 1M
- -5,6 %
MRNA · Nasdaq · ·
223,22 $-3,5 %Schluss 13. Nov.
Zahlen bis 30. September 2026, aus dem 10-Q vom 6. November 2026
Just reported
From Moderna's results release of 6. November 2026; its quarterly report has since been filed.
Actual
1,31B $
+29 % y/y
Guided
—
No guide given
Actual
0,38 $
Guided
—
No guide given
Actual
130M $
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →The themes Moderna is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B $A+
EXELExelixis, Inc.16,8B $A+
JAZZJazz Pharmaceuticals plc15,5B $A
TECHBIO-Techne Corp11,4B $A+
HALOHalozyme Therapeutics, Inc.11,4B $A+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28. Okt. 2026CAGraded C, now ADie Umsatzanteile sind Schätzungen für year ended 2025-12-31 und keine Zahlen aus einem eingereichten Bericht.
Spikevax
A COVID-19 vaccine updated to target circulating virus variants.
mNEXSPIKE
A COVID-19 vaccine that uses a lower mRNA dose than Spikevax and focuses the immune response on key parts of the virus.
mRESVIA
An RSV vaccine for older adults and certain adults at increased risk of severe RSV illness.
mFLUSIVA
An influenza vaccine approved in the United States and Canada for adults aged 50 and older; commercial sales began in September 2026.
mCOMBRIAX
A vaccine combining protection against influenza and COVID-19, authorized in Europe and Canada for adults aged 50 and older; it had not been commercialized by September 30, 2026.
Intismeran autogene (mRNA-4157)
An investigational personalized cancer treatment designed around mutations in an individual patient's tumor; it is being developed with Merck alongside pembrolizumab.
Moderna makes vaccines using messenger RNA (mRNA), which gives cells instructions to make a protein that can help prevent or treat disease. It also develops mRNA-based treatments, including a personalized cancer treatment being developed with Merck and treatments for rare inherited diseases. As of September 30, 2026, it had five approved products, though its flu-plus-COVID vaccine had not yet been commercialized.
Gebaut aus den eigenen Einreichungen von Moderna, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
Moderna sells COVID-19 vaccines mainly to wholesalers, distributors and governments, plus vaccines for respiratory syncytial virus (RSV) and influenza.
Grade C-
Das Band unter dem Kurs zeigt die Note an jedem Tag – gebildet nur aus den Unterlagen, die bis dahin veröffentlicht waren.
Zeigt 2 von 32 Quartalen der Notenhistorie von Moderna, Inc.. Die übrigen 30 reichen zurück bis März 2019.
